Pneumosolv Special Precautions

Cross-sensitivity and/or related problems: Patients allergic to one cephalosporin may be allergic to other cephalosporins.
Patients allergic to penicillins, penicillin derivative, or penicillamine may be allergic to cephalosporins.
Carcinogenicity: Long-term studies in animals to evaluate the carcinogenic potential of these cephalosporins have not been done.
Mutagenicity: Studies have not shown that these cephalosporins are mutagenic.
Dental: Long-term therapy with cephalosporins may allow for the overgrowth of Candida albicans, resulting in oral candidiasis.
Fertility: Adequate and well-controlled studies in humans have not been done.
Use in Pregnancy: Cross the placenta. Adequate and well-controlled studies in humans have not been done. However, studies in animals have not shown that these cephalosporins cause adverse effects in the fetus.
Use in Lactation: Distributed into breast milk, usually in low concentrations. However, problems in humans have not been documented to date.
Use in Children: Lower metabolic and/or renal clearance of cephalosporins, with resulting prolonged half-life, has been reported in newborn infants. However, Ceftriaxone has been found to have shorter half-life in infants than it does in adults.
Because Ceftriaxone is very highly bound to plasma proteins, it may be more likely than some other cephalosporins to displace bilirubin from serum albumin. Ceftriaxone should be used with caution in hyperbilirubinemic neonates, especially premature neonates.
Use in Elderly: Cephalosporins have been used in the geriatric population, and no-geriatrics-specific problems has been documented to date. However, elderly patients are more likely to have an age-related decrease in renal function, which may require adjustment in dosage and/or dosing interval in patients receiving cephalosporins.